mycophenolic-acid and Gingival-Diseases

mycophenolic-acid has been researched along with Gingival-Diseases* in 4 studies

Other Studies

4 other study(ies) available for mycophenolic-acid and Gingival-Diseases

ArticleYear
[Mysterious gingival ulcers].
    Annales de pathologie, 2017, Volume: 37, Issue:2

    Topics: Adult; Epstein-Barr Virus Infections; Female; Gingival Diseases; Glomerulonephritis, Membranoproliferative; Humans; Immunocompromised Host; Immunosuppressive Agents; Mycophenolic Acid; Oral Ulcer; Reed-Sternberg Cells; RNA, Viral

2017
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
    American journal of hematology, 2010, Volume: 85, Issue:8

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Diagnosis, Differential; Drug Therapy, Combination; Epstein-Barr Virus Infections; Female; Gingival Diseases; Hepatitis, Autoimmune; Herpesvirus 4, Human; Hodgkin Disease; Humans; Iatrogenic Disease; Immunocompromised Host; Immunosuppressive Agents; Lymphoproliferative Disorders; Mandibular Diseases; Mycophenolic Acid; Oral Ulcer; Prednisone; Remission Induction; Rituximab; Virus Activation

2010
Successful treatment of oral linear IgA disease using mycophenolate.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:4

    Linear IgA disease (LAD) is a rare acquired autoimmune bullous disorder, characterized by linear deposition of IgA along the dermoepidermal basement membrane zone. The clinical presentation of LAD consists of vesiculobullous lesions affecting the skin and mucosal surfaces. The present case report presents a rare presentation of this vesiculobullous disorder. Although more than 50% of LAD patients present with oral lesions, there are few reported cases of involvement of the mouth as the sole manifestation. A 79-year-old female presented with a sore mouth and erosions affecting the palate. The symptoms resolved following the provision of mycophenolate, an antiproliferative immunosuppressant which has not previously appeared to have been reported in the long-term successful management of linear IgA disease limited to the mouth. We found that mycophenolate is a useful adjunct to the successful treatment of oral linear IgA when the uses of other immunosuppressants are contraindicated.

    Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Diagnosis, Differential; Female; Fluorescent Antibody Technique; Fluorescent Antibody Technique, Direct; Gingival Diseases; Humans; Immunoglobulin A; Immunosuppressive Agents; Mycophenolic Acid; Oral Ulcer; Prednisolone; Skin Diseases, Vesiculobullous

2007
Pharmacodynamic monitoring of the conversion of cyclosporine to tacrolimus in heart and lung transplant recipients.
    Transplantation proceedings, 2005, Volume: 37, Issue:10

    Conversion from cyclosporine (CsA) to tacrolimus (TRL) remains challenging in the daily routine due to individual variations in blood concentrations (pharmacokinetics, PK), pharmacodynamics (PD) and in interactions on plasma mycophenolic acid (MPA) concentrations. Therefore, we used our PD assays of lymphocyte function to monitor the conversion of CsA to TRL in heart (HTx) and lung (LTx) transplant recipients.. Patients (six HTx, two LTx) were converted from CsA to TRL because of gingival hyperplasia. All patients were treated with 6 mg BID TRL 24 hours after the last CsA dose and received mycophenolate mofetil BID cotherapy. PK measurements of CsA, TRL, and MPA were done by EMIT. Expression of cytokine production (IL-2, TNF-alpha), lymphocyte proliferation (PCNA), and activation (CD25) was assessed by FACS.. TRL concentrations increased from day 1 to 3, but did not alter MPA concentrations, which were comparably high to MPA concentrations in combination with CsA (day 0). Compared to CsA therapy, increased TRL concentrations did not further inhibit PCNA expression, inhibited CD25 expression less on days 1 and 2 and equally high on day 3, but inhibited expression of IL-2 and TNF-alpha significantly higher on days 2 and 3 (P < .05).. This study shows that monitoring PD of lymphocyte functions after conversion from CsA to TRL in HTx and LTx recipients revealed differences of inhibition of lymphocyte functions. Monitoring PD of lymphocyte function may provide insights in drug interactions of immunosuppressive combination therapy and may help to tailor immunosuppression to avoid toxicity and to enhance efficacy.

    Topics: Cyclosporine; Drug Monitoring; Drug Therapy, Combination; Gingival Diseases; Heart Transplantation; Humans; Hyperplasia; Immunosuppressive Agents; Lung Transplantation; Metabolic Clearance Rate; Mycophenolic Acid; Tacrolimus

2005